European Society of Endocrinology

EU Legislative Interests

• Classification Labelling and Packaging regulation (CLP). • Registration, Evaluation, Authorisation and Restriction of Chemicals Regulation (REACH). • Chemicals Strategy for Sustainability. • European Beating Cancer Plan. • European Health Data Space (EHDS). • In Vitro Diagnostic Medical Devices Regulation (IVDR).

Communication Activities

1. Publication of the White Paper Hormones in European Health Policies, How Endocrinologist can contribute towards a healthier Europe (May 2021). 2. Publication of 'the Milano Declaration' Recognising the Key Role of Hormones European Health (May 2022). 3. Publication of 'Ten recommendations for Good Hormone Health' Annex of the Milano Declaration (May 2023). 4. European Hormone Day 'Because Hormones Matter' - Building Public and Policy Awareness for the Role of Hormones in Public Health - 24 April 2025. 5. Response to consultations in the field of the policies listed above. (CLP Regulation, BPA, European Health Data Space, PFAS regulation, and others). 6. Participation and support to the event 'Shaping an ambitious legislative framework for Endocrine Disruptors' - a high level panel discussion on the gaps between science and legislation' - (European Parliament - Brussels) - 7 June 2023 7. Participation to the Annual European Commission Endocrine Disruptors Forum (Brussels, October 2023 - October 2024). 8. Participation to the BE EU Presidency Event (April 2024) on chemicals legislation - ESE expert speaker Pr. R. Peeters - Erasmus University Rotterdam, NL 9. Engagement with European Commission related to the REACH Legislative Proposal (March 2025) -cabinet of Commissioners Ribera and Rosswall 10.Engagement with members of the European Parliament related to the REACH Legislative process (March 2025) 11.Organisation of the event: Minimizing the impact of Endocrine Disrupting Chemicals on Health and Environment: a scientific update. 14 May 2025 (Copenhagen) with representation of European Commission DG ENV and Member of European Parliament 12. Statements issued towards the consultation on the Cosmetic Products Regulation , Chemicals Omnibus and Chemicals Action Plan (July 2025) 13. Open Letter calling on the EU Member States to act on Endocrine Disrupting Chemicals (July 2025) 14.0 Statement on PFAS restriction proposal (October 2025)

Interests Represented

Does not represent commercial interests

Member Of

The European Society of Endocrinology is member of 1. The Alliance for Biomedical Research in Europe (Biomed Alliance): https://www.biomedeurope.org/ 2. The European Cancer Organisation: https://www.europeancancer.org/ The European Society of Endocrinology is associated to other Endocrine societies around the world. These organizations can be found at https://www.ese-hormones.org/membership/organisational-memberships/associate-partner-societies/

Organisation Members

ESE has an individual membership exceeding 5200 (Oct 2025) endocrine health care professionals from close to 100 countries. These represent the spectrum of clinical care, basic science and the translational research inbetween. Nursing staff and medical students / physicians in training can also apply for membership. Individual membership applications are approved by the ESE Executive Committee. ESE has formal affiliations and organizational membership with 50 National endocrine societies across geographical Europe as well as 15 specialist partner societies, dedicated to their respective and specific fields of endocrinology. A full list of these societies can be found here: https://www.ese-hormones.org/about-us/our-communities/ese-council-of-affiliated-societies/ ESE also has formal affiliations with 31 Patient Advocacy and support groups covering the diverse spectrum of endocrinology disease: https://www.ese-hormones.org/membership/membership-information/other-memberships/patient-advocacy-group-affiliated-membership/ ESE also has Corporate Members. Corporate members are companies operating within the field of endocrinology and responding to the below criteria: • Has a scientific, diagnostic, technical, or clinical focus, and • Works in, or is associated with, any of the 8 different areas of endocrinology • Is developing or commercialising products or services at any stage of their life cycle. Applications for Corporate Membership are reviewed and approved by the ESE Executive Committee. https://www.ese-hormones.org/membership/organisational-memberships/corporate-membership/ Present members (Full year 2025) include Esteve Pharma, Recordati Rare Diseases, Novo Nordisk, Ascendis Pharma, Diurnal, Neurocrine Biosciences, Uni-Pharma, Crinetics, Horizon Therapeutics (now Amgen), Ipsen, Alexion, Innozyme pharma, Amolyt, BridgeBio, KiowaKirin and Camurus ESE is a partner to the European Reference Network for Rare Endocrine Disorders - endo-ERN. https://endo-ern.eu/partners/

Additional Information

Income listed under Oxford University Press relates to royalty income from the scientific journal 'European Journal of Endocrinology, fully owned by the European Society of Endocrinology. Income listed under JointEndo is a gift to the Society from the Joint Venture JointEndo that the European Society of Endocrinology and the European Society of Paediatric Endocrinology have set up to manage their Joint 2025 Congress. Membership fees amount to 729 838 €, with Industry membership accounting for 266 000 €. As this stays below the 10% tresshold, no further details are provided. ESE provides full transparency eg towards the European Medicine Agency.